Drugs / NB004
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05036291 | Oct 2021 → Sep 2025 | cancer or benign tumor | Ningbo Newbay Technology Development Co., Ltd | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NB004 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05036291 ↗ |
| Route | Oral | “NB004 tablets will be administered orally once daily for repeated 28-day cycles until discontinuation criteria are met.” NCT05036291 ↗ |